文献速递糖尿病

1型糖尿病年龄非依赖免疫亚型显示不同进展速率与免疫治疗反应

Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses.
PubMed 文献 · Diabetologia · 2026-07-11

该研究分析6项免疫治疗试验中560例新发1型糖尿病患者的干预前样本,采用血浆诱导转录生物测定。基线转录组聚类识别出两个免疫亚型,与平均年龄无关且纵向稳定。亚型1以中性/低风险HLA、C肽下降快、Th1升高和对anti-CD20反应好为特征;亚型2以胰岛素自身抗体、特定miRNA升高和对CTLA4-Ig反应好为特征。

要点

  • 新发1型糖尿病可基于血浆诱导转录分为两个稳定免疫亚型。
  • 亚型1特征为C肽下降快、Th1升高,对anti-CD20反应更好。
  • 亚型2特征为胰岛素自身抗体和特定miRNA升高,对CTLA4-Ig反应更好。

核心结论

  • 研究支持1型糖尿病存在免疫学上不同的亚组,并提示未来可能开展靶向治疗干预。

研究设计与样本

  • 分析6项免疫治疗试验中560例参与者干预前样本,使用血浆诱导转录生物测定和标准化报告细胞群。

主要发现

  • 基线转录组分析在至少5项试验中识别出2854个高变异转录本。
  • 无监督聚类将参与者分为两个亚组,平均年龄无差异,分类在基线后纵向样本中保持稳定(p=1.4 × 10-14)。
  • 亚型1富集中性/低风险HLA单倍型参与者,最年轻参与者C肽下降速率最快(p<0.05)。
  • 亚型1血浆细胞因子和趋化因子升高、循环CD4+CXCR3+CCR6- Th1细胞增加(p<0.05),对anti-CD20治疗反应更好。
  • 亚型2富集胰岛素自身抗体滴度个体,血浆miR-155-5p和miR-409-3p较高(p<0.05),对CTLA4-Ig反应更好,与CD4+CD45RO+CD62L+中央记忆T细胞更大程度减少(p=8.1 × 10-5)和调节性T细胞保留(p=0.02)相关。

临床怎么用

  • 新发1型糖尿病可考虑基于免疫亚型分层,以匹配anti-CD20或CTLA4-Ig等靶向治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The development of improved prevention and treatment strategies for type 1 diabetes requires a deeper understanding of its heterogeneity. Our aim was to measure immunological heterogeneity among individuals with new-onset type 1 diabetes using plasma-induced transcription, bioinformatics tools and targeted follow-up analyses. METHODS: We analysed pre-intervention samples from 560 participants across six immunotherapy trials, using a plasma-induced transcriptional bioassay and a standardised reporter cell population. RESULTS: Transcriptomic profiling at baseline identified 2854 transcripts with high variation in at least five trials. Unsupervised clustering divided the participants into two subgroups that did not differ in mean age and whose classifications remained stable in post-baseline longitudinal samples, suggesting that subgroup assignments were not driven by transient relapsing and remitting immune activity (p=1.4 × 10-14). Phenotypic analyses and an independent new-onset type 1 diabetes cohort found subgroup 1 enriched for participants with neutral or low-risk HLA haplotypes and the youngest participants possessing the most rapid rate of C-peptide decline (p<0.05). This subgroup showed elevated plasma cytokine and chemokine levels, increased circulating CD4+CXCR3+CCR6- Th1 T cells (p<0.05) and better therapeutic responses to anti-CD20. Subgroup 2 was enriched for individuals possessing insulin autoantibody titres, higher plasma miR-155-5p and miR-409-3p (p<0.05) and a better therapeutic response to CTLA4-Ig that was linked to a greater reduction in CD4+CD45RO+CD62L+ central memory T cells (p=8.1 × 10-5) and retention of regulatory T cells (p=0.02). CONCLUSIONS/INTERPRETATION: These findings support the existence of immunologically distinct type 1 diabetes subgroups and the possibility of future targeted therapeutic interventions. DATA AVAILABILITY: All microarray gene expression data files have been deposited at The National Center for Biotechnology Information Gene Expression Omnibus (accession no. GSE302205).

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Bedrat A, Truchan NA, Pant T, et al. Age-independent immune subtypes in type 1 diabetes exhibit distinct post-onset progression rates and immunotherapeutic responses. Diabetologia. 2026. PMID: 42432282. doi:10.1007/s00125-026-06794-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。